head shot image

Quanyin Hu, PhD

Assistant Professor

The ultimate goal of our laboratory is to leverage delivery approach to address current clinical challenges and facilitate translational research by combining cell therapy, immunotherapy and personalized therapy. Specifically, by adapting the concept of “CIPT”, we are getting inspiration from natural cells to design our delivery tools and particularly interested in engineering cells and cell derivatives as vehicles for delivery of small/macro molecules, proteins, and antibodies to treat a broad array of diseases, including cancer, infectious disease and auto immune disease. We are also leveraging the interaction between synthetic materials and immune cells to modulate immune response in a controllable fashion. To advance the personalized therapy, neoantigen-based vaccination and microbiota research will be emphasized in our lab to transform traditional “one-size-fit-all” treatment to precision medicine for each individual.

Prof. Hu received his Ph.D. degree in Biomedical Engineering from the University of North Carolina at Chapel Hill and North Carolina State University under the supervision of Prof. Zhen Gu in 2018. From 2018-2020, he was a postdoc associate in the laboratory of Prof. Robert Langer in Koch Institute for Integrative Cancer Research at MIT. Prof. Hu joined UW-Madison in 2020 as an assistant professor in the Pharmaceutical Sciences Division at the School of Pharmacy.

2020-present, Assistant Professor, Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison Wisconsin, USA                                                                                                     

2018-2020, Postdoc Associate, Koch Institute for Integrative Cancer Research, Department of Chemical Engineering Massachusetts, Massachusetts Institute of Technology (MIT), USA                                             

2014-2018, Ph.D. Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill | North Carolina State University, USA                                          

2011-2014, M.S. Fudan University, Pharmaceutics, Shanghai, China                                                             

2007-2011, B.E. China Pharmaceutical University, Nanjing, China    

Highlighted Publications:

(* corresponding author; # equal contribution)

17. Yixin Wang,# Zhaoting Li#, Afton Martin LaMere, Quanyin Hu*, in revision, Chemical Society Reviews.​

16. Zhaoting Li, Fanyi Mo, Yixin Wang, Wen Li, Yu Chen, Jun Liu, Ting-Jing Chen-Mayfield, Quanyin Hu*, "Enhancing Gasdermin-induced tumor pyroptosis through preventing ESCRT-dependent cell membrane repair augments antitumor immune response", Nature Communications, 13, 6321, 2022. 

15. Jun Liu, Yixin Wang, William Heelan, Yu Chen, Zhaoting Li, Quanyin Hu*, in press, Science Advances.​

14. Yu Chen, Iran Tandon, Yixin Wang, Weiping Tang*, Quanyin Hu*, Proteolysis-targeting chimera (PROTAC) delivery system: advancing protein degraders towards clinical translation",  Chemical Society Reviews.​ 51, 5330-5350, 2022

13. Chen Chen#, Weiqiang Jing#, Yu Chen, Ganyu Wang, Mohnad Abdalla, Lin Gao, Maosen Han, Chongdeng Shi, Anning Li, Peng Sun, Xin Jiang, Zhenmei Yang, Shengchang Zhang, Jing Zhang, Chunwei Tang, Ying Liu, Rui Zhang, Fengbo Xu, Baixiang Dong, Xueen Li, Minglu Liu, Bangming Qiang, Yanhua Sun, Xia Wei, Jun Li, Quanyin Hu*, Xinyi Jiang*. "Intracavity generation of glioma stem cell–specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy",  Science Translational Medicine, 14, eabn1128, 2022..

12. Yu Chen, Samira Pal, Quanyin Hu*, "Recent advances in biomaterial-assisted cell therapy", Journal of Materials Chemistry B (invited manuscript), 2022​

11. Caroline Hopkins#, Kaila Javius-Jones#, Yixin Wang, Quanyin Hu*, Seungpyo Hong*, in press, Expert Opinion on Drug Delivery (invited manuscript), 2022.

10. Zhaoting Li#, Yingyue Ding#, Jun Liu, Jason Wang, Luna Mo, Yixin Wang, Paul Sondel, Seungpyo Hong, Quanyin Hu*. "Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment", 13, 1845, 2022. Nature Communications. DOI:

9. Yingyue Ding, Yixin Wang, Quanyin Hu*. "Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy", Exploration, 2022, DOI:10.1002/EXP.20210106.

8. Yixin Wang, Ting-Jing Chen-Mayfield, Zhaoting Li, Muhsin Younis, Weibo Cai*, Quanyin Hu*. "Harnessing DNA for Immunotherapy: Cancer, Infectious Diseases, and Beyond", Advanced Functional Materials, 2022, 2112273. DOI: 10.1002/adfm.202112273

​7. J. Liu, W. Li, Y. Wang, Y. Ding, A. Lee, Q. Hu*. "Biomaterials coating for on-demand bacteria delivery: Selective release, adhesion, and detachment", Nano Today, 2021, 4, 101291. DOI: 10.1016/j.nantod.2021.101291​​

6. Y. Wang, Z. Li, L. Mo, Z. Gu*, Q. Hu*. "Engineered Platelets: Advocates for tumor immunotherapy", Nano Today, in press, 2021.

5. Y. Ding#, Z. Li#, A. Jaklenec, Q. Hu*. "Vaccine delivery systems toward lymph nodes", Advanced Drug Delivery Reviews. (Invited review). DOI: 10.1016/j.addr.2021.113914

4. Z. Li, Y. Wang, J. Liu, P. Rawding, J. Bu, S. Hong, Q. Hu*, "Chemically and Biologically Engineered Bacteria-Based Delivery Systems for Emerging Diagnosis and Advanced Therapy",  Advanced Materials, 2021. DOI: 10.1002/adma.202102580

3. Q. Hu, H. Li, E. Ogunnaike, Q. Chen, H. Ruan, S. Ahn, E. Dukhovlinova, K. Yang, D. Wen, G. Dotti*, Z. Gu*; "Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets", Nature Biomedical Engineering, 2021. DOI: 10.1038/s41551-021-00712-1

2. Y. Wang, Z. Li, Q. Hu*; "Emerging self-regulated micro/nano drug delivery devices: A step forward towards intelligent diagnosis and therapy". Nano Today, 2021. DOI: j.nantod.2021.101127

1. Z. Li, Y. Wang, Y. Ding, L. Repp, GS Kwon, Q. Hu*; "Cell‐Based Delivery Systems: Emerging Carriers for Immunotherapy". Advanced Functional Materials, 2021. DOI:adfm.202100088.